EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Addressing current challenges in optimization of lipid management following an ACS event: Outcomes of the ACS EuroPath III initiative

Alberico L Catapano, Raffaele De Caterina, J Wouter Jukema, Robert Klempfner, Ulf Landmesser, François Schiele, Alessandro Sionis

Clinical Cardiology · 2023

DOI: 10.1002/clc.23988 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Cardiology, 2023. Verfasst von Alberico L Catapano und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Atherosclerosis, Hydroxymethylglutaryl-CoA Reductase Inhibitors. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanofi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Low‐density lipoprotein cholesterol (LDL‐C) lowering is key to reduce atherosclerotic disease progression and recurrent events for patients after acute coronary syndrome (ACS). However, LDL‐C management for post‐ACS patients remains challenging in clinical practice. Hypothesis The ACS EuroPath III project was designed to optimize LDL‐C management in post‐ACS patients by promoting guideline implementation and translating existing evidence into effective actions.

Methods

Three surveys targeting cardiologists ( n = 555), general practitioners (GPs; n = 445), and patients ( n = 662) were conducted in Europe, with the aim of capturing information on patient characteristics and treatment during acute phase, discharge and follow‐up. GPs’ and patients’ opinions on key treatment aspects were also collected. Based on survey results, international experts and clinicians identified areas of improvement and generated prototype solutions. Participants voted to select the most feasible and replicable proposals for co‐development and implementation.

Results

Five key areas of improvement were identified: (1) inappropriate treatment prescribed at discharge; (2) lack of lipid guidance in the discharge letter; (3) inadequate lipid‐lowering therapy (LLT) optimization; (4) gaps in guideline knowledge and lack of referral practices for GPs; (5) patients’ concerns about lipid management. Proposed solutions for these focus areas included development of a treatment algorithm for the acute phase, a standardized GP discharge letter, an assessment tool for LLT efficacy at follow‐up, an education plan for GPs/patients and a patient engagement discharge kit. The standardized GP discharge letter and treatment algorithm have been selected as the highest priority solutions for development.

Conclusion

These initiatives have the potential to improve adherence to guidelines and patient management after ACS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Coronary SyndromeAtherosclerosisHydroxymethylglutaryl-CoA Reductase InhibitorsHumansCholesterol, LDLEuropePatient Discharge

Stichwörter der Autor:innen

LDL cholesterolPCSK9 inhibitorsacute coronary syndromescardiovascular risklipid-lowering treatmentsmyocardial infarction

Substanzen

Cholesterol, LDLHydroxymethylglutaryl-CoA Reductase Inhibitors

Autor:innen und Institutionen

  • Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy.
  • Division of Cardiovascular, Department of Cardiothoracic and Vascular, Pisa University Hospital, University of Pisa, Pisa, Azienda Ospedaliero-Universitaria Pisana, Pisa, and Fondazione Villaserena per la Ricerca, Città…
  • Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands.
  • Netherlands Heart Institute, Utrecht, The Netherlands.
  • Cardiac Rehabilitation Institute, Sheba Medical Center, Tel-Aviv University, Tel Aviv, Israel.
  • Department of Cardiology, Charité University Medicine Berlin, German Centre for Cardiovascular Research (DZHK), Partner Site Berlin, Berlin Institute of Health (BIH), Berlin, Germany.

Förderung

  • Sanofi

Zitieren

APA

Catapano, A. L., De Caterina, R., Jukema, J. W., Klempfner, R., Landmesser, U., Schiele, F., & Sionis, A. (2023). Addressing current challenges in optimization of lipid management following an ACS event: Outcomes of the ACS EuroPath III initiative. Clinical Cardiology. https://doi.org/10.1002/clc.23988

Vancouver

Catapano AL, De Caterina R, Jukema JW, Klempfner R, Landmesser U, Schiele F, et al. Addressing current challenges in optimization of lipid management following an ACS event: Outcomes of the ACS EuroPath III initiative. Clinical Cardiology. 2023. doi:10.1002/clc.23988

BibTeX
@article{Catapano2023,
  author = {Catapano, Alberico L and De Caterina, Raffaele and Jukema, J Wouter and Klempfner, Robert and Landmesser, Ulf and Schiele, François and Sionis, Alessandro},
  title = {Addressing current challenges in optimization of lipid management following an ACS event: Outcomes of the ACS EuroPath III initiative},
  journal = {Clinical Cardiology},
  year = {2023},
  doi = {10.1002/clc.23988}
}
Kostenlos starten →